Lightnews — Scholar-powered news

Reposted by Saad Z. Usmani, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · 24d

Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.

🗓️ Thursday, September 18 | 4:40 p.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

3 9

Reposted by Saad Z. Usmani, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · 23d

Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm

🗓️ Friday, September 19 | 9:40 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social

3 5

Reposted by Saad Z. Usmani, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · 22d

At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm

🗓️ Saturday, September 20 | 9:20 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social

2 4

Reposted by Saad Z. Usmani, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · 29d

MSK is headed to Toronto for #IMS25! Stay tuned for posters and presentations that are advancing #multiplemyeloma research and treatments. #mmsm

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

Myeloma Society @myeloma-society.bsky.social · Sep 12

⏳We are less than one week away from #IMS25 in Toronto! Get ready for world-class insights, valuable networking, and meaningful innovation. If you can’t join us in person, you can still take part virtually. 💻 Register now ➡️ rb.gy/139j28

2 5

Reposted by Saad Z. Usmani, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · 25d

MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm

🗓️ Wednesday, September 17 | 11:10 a.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

2 4

Reposted by Saad Z. Usmani, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · 25d

At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma.

🗓️ Wednesday, September 17 | 12:14 p.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

2 5

Reposted by Saad Z. Usmani, MD

OncLive @onclive.bsky.social · Sep 11

Sign up to read exclusive expert insights on key abstracts to watch at #IMS25! @szusmani.bsky.social @mskcancercenter.bsky.social @myeloma-society.bsky.social #mmsm
www.onclive.com/view/experts...

2 2

Reposted by Saad Z. Usmani, MD

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · Jun 2

Join Dr. @szusmani.bsky.social as he presents research on "Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed #MM (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study" at #ASCO25. @ascocancer.bsky.social

2 6

Reposted by Saad Z. Usmani, MD

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · Jun 2

"The phase 3 CEPHEUS trial previously demonstrated improved efficacy outcomes with DVRd vs VRd in patients with TIE or transplant-differed NDMM," shares myeloma specialist
@szusmani.bsky.social during his session at #ASCO25.

@ascocancer.bsky.social

2 9

Reposted by Saad Z. Usmani, MD

OncLive @onclive.bsky.social · Jun 2

D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma @ascocancer.bsky.social @mskcancercenter.bsky.social @szusmani.bsky.social #ASCO25 #mmsm www.onclive.com/view/d-vrd-r...

D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma

D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.

www.onclive.com

2 5

Reposted by Saad Z. Usmani, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · May 7

Congrats to Mark G. Kris, Kenneth Offit, David G. Pfister, and
@szusmani.bsky.social on being inducted into the 13th Giants of Cancer Care® class by @onclive.bsky.social! This award honors leading physicians who are advancing #cancerresearch. @mskcancercenter.bsky.social
Learn more: bit.ly/42Ox58M

3 8

Reposted by Saad Z. Usmani, MD

International Myeloma Foundation @imfmyeloma.bsky.social · Mar 7

❤️ Thank you, Dr. Usmani for continuing to support #MyelomaICE!

1 2

Saad Z. Usmani, MD @szusmani.bsky.social · Mar 7

Dear all, putting in a plug for the International Myeloma Foundation Iceland Cycling Expedition 2025 below. Thanks for your generosity last year, many of you contributed to its success. Every donation and any amount counts.
@imfmyeloma.bsky.social
fundraise.myeloma.org/fundraiser/5...

Iceland Cycling Expedition

fundraise.myeloma.org

1 3 5

Reposted by Saad Z. Usmani, MD

Anish Simhal @aksimhal.bsky.social · Feb 21

1/ 🚨New research alert! 🚨Our study in Blood Cancer shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma, with @joedeasy.bsky.social, @malinhultcrantz.bsky.social, @szusmani.bsky.social, and the rest of the @mskcancercenter.bsky.social team! 🧵👇#MyelomaSky

1 3 8

Reposted by Saad Z. Usmani, MD

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · Feb 6

NEW in @natmedicine.bsky.social: Results from a phase 3 clinical trial led by MSK's #myeloma specialist & cellular therapist @szusmani.bsky.social. Learn more: www.nature.com/articles/s41...

MSK Department of Medicine @mskdeptofmed.bsky.social · Feb 6

A phase 3 clinical trial led by @szusmani.bsky.social found that a combination of four therapies significantly improved outcomes for people with transplant-ineligible newly diagnosed #multiplemyeloma. #mmsm @mskcancercenter.bsky.social @natmedicine.bsky.social
www.nature.com/articles/s41...

5 12

Saad Z. Usmani, MD @szusmani.bsky.social · Feb 6

Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽
#MyelomaSky

@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social

www.nature.com/articles/s41...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - Nature Medicine

In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and d...

www.nature.com

3 11

Reposted by Saad Z. Usmani, MD

DrMHB @drmhb.bsky.social · Dec 18

Thanks to @szusmani.bsky.social for donating 🙌🏾🙌🏾🙌🏾🥳🥳🥳 to support multiple myeloma cancer research @ give.themmrf.org/fundraiser/5...

2024 MM4MM: Mount Kilimanjaro

give.themmrf.org

1 3

Reposted by Saad Z. Usmani, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · Dec 10

This is your last chance to see incredible research at the #ASH24 poster session today! Don't miss posters by Drs. Gunjan Shah, Carlyn Rose Tan, & Pallawi Torka. @mskcancercenter.bsky.social @szusmani.bsky.social

6-8 p.m. PST
https://buff.ly/3ZLbSey
https://buff.ly/3OOjjeG
https://buff.ly/3Vum0Wv

3 8

Reposted by Saad Z. Usmani, MD

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · Dec 8

Congratulations to MSK's Dr. Urvi Shah for being awarded the @ash-hematology.bsky.social David M. Goldenberg Clinical Research Training Institute Award for her work on research that shows that a high-fiber, plant-based dietary intervention may delay progression #MGUS/#SMM to #MM.

#ASH24 #ASHKudos

8 32

Reposted by Saad Z. Usmani, MD

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · Dec 8

Dr. @szusmani.bsky.social presents on “Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept” that is part of the ASH Research Collaborative Multiple Myeloma Network at @ash-hematology.bsky.social.

#ASH24

6 15

Saad Z. Usmani, MD @szusmani.bsky.social · Dec 8

Please join us now #ASH24
#MyelomaSky
ASH RESEARCH COLLABORATIVE MULTIPLE MYELOMA NETWORK: ACCELERATING RESEARCH AND COLLABORATIVE CLINICAL CARE THROUGH REAL-WORLD EVIDENCE GENERATION
December 7, 2024, 4:00 p.m. - 5:30 p.m.
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

1 7

Reposted by Saad Z. Usmani, MD

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · Dec 7

#ASH24: Join myeloma specialist Dr. @szusmani.bsky.social for his presentation on "Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept" today at 4pm PT at @ash-hematology.bsky.social.

bit.ly/49vscmW

3 7

Reposted by Saad Z. Usmani, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · Dec 7

Join Kylee Maclachlan for the presentation "Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease."

2:15 pm PST. #ASH24 @mskcancercenter.bsky.social
@szusmani.bsky.social @ash-hematology.bsky.social
buff.ly/4f6J3gP

2 2

Reposted by Saad Z. Usmani, MD

American Society of Hematology @ash.hematology.org · Dec 5

☀️ Awaken your inner poet and write your best haiku about #ASH24 or #hematology! That's 3 lines in a 5-7-5 syllable pattern.

Post now through Tuesday afternoon and include #ASHaiku. You might get included in a highlights post!

🛑Remember, there's only one H in #ASHaiku!

#HemeSky #Hematology

3 8

Saad Z. Usmani, MD @szusmani.bsky.social · Dec 5

592 Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
ash.confex.com/ash/2024/web...